This meeting took place in 2015


Here are the related meetings in 2019:
Antibodies as Drugs: New Horizons in the Therapeutic Use of Engineered Antibodies (D2)

For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Antibodies as Drugs: Immunological Scaffolds as Therapeutics (J8)


Organizer(s) Pablo Umaña, Mark X. Sliwkowski and Martin J. Glennie
February 8—13, 2015
Fairmont Banff Springs • Banff, Alberta Canada
Discounted Abstract Deadline: Oct 9, 2014
Abstract Deadline: Nov 12, 2014
Scholarship Deadline: Oct 9, 2014
Discounted Registration Deadline: Dec 9, 2014

Sponsored by Genentech, Inc., ImmunoGen, Inc., Mersana Therapeutics, OncoMed Pharmaceuticals, Inc., Pfizer Inc., Regeneron Pharmaceuticals, Inc. and Shire Human Genetic Therapies


Summary of Meeting:
Monoclonal antibodies are now an established class of drugs in oncology and inflammation. In addition, exciting progress has been recently made on next-generation, engineered therapeutic antibodies and alternative immunological scaffolds, with the first examples from this class being recently approved by the FDA and EMA. This Keystone Symposia meeting will review progress in this area, including lessons learned in the clinic and how this can be applied to new targets and drug candidates. The meeting will cover major areas of activity including: 1) Increasing antibody potency via antibody engineering, better engaging immune effector cells, and improvements in targeted delivery of effectors via fusion proteins and via conjugation of cytotoxic drugs; 2) Applying alternative targeting approaches to increase the therapeutic window, such as pre-targeting and site-specific antibody unmasking; 3) Novel antibodies in areas outside of oncology, including infectious diseases, neurology and chronic inflammation; 4) Engineering antibodies and scaffolds for alternative delivery routes and improved disposition; 5) Clinical progress with multi-specific antibodies; and 6) Recent advances in (i) addressing difficult targets such as GPCRs and ion channels, (ii) alternative immunological scaffolds, and (iii) novel antibody library technologies. Opportunities for interdisciplinary interactions will be significantly enhanced by the concurrent meeting on “Tumor Immunology - Multidisciplinary Science Driving Combination Therapy,” which will be co-located with this meeting.

View Meeting Program

Scholarships/Awards

National Institute of General Medical Sciences (NIGMS) Ancillary Training Program Scholarship Recipients

Michael-Paul Robinson
Cornell University, USA

National Institute of Allergy and Infectious Diseases (NIAID) Scholarship Recipients

Jaspreet S. Batra
Weill Cornell Medical College, USA

Joseph J. Bellucci
Duke University, USA

Malgorzata Bobrowicz
Medical University of Warsaw, Poland

Marijn A. Gillissen
Aimm Therapeutics / AMC, Netherlands

Einav Vax
Tel-Aviv University, Israel